Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGHT: Aflibercept vs PDT in Chinese wAMD
NCT01482910Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2011
- Primary completion
- Mar 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in exudative macular degeneration, sponsored by Bayer. Started Dec 2011; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01482910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01482910.